Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $76 to $85
Guggenheim Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,030
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Goldman Sachs Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
Barclays Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $76 to $85
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $381
Jefferies Adjusts Merck & Company Price Target to $147 From $150
Gilead Sciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO) and Gilead Sciences (GILD)
HSBC Adjusts Price Target on Eli Lilly and Co. to $1,150 From $1,100, Maintains Buy Rating
Hold Rating on Gilead Sciences Amid Modest PBC Market Impact
Analysts Conflicted on These Healthcare Names: Arcutis Biotherapeutics (ARQT), Gilead Sciences (GILD) and Cardinal Health (CAH)
Barclays Sticks to Their Hold Rating for Gilead Sciences (GILD)
Berenberg Bank Maintains GlaxoSmithKline(GSK.US) With Buy Rating, Maintains Target Price $46
Eli Lilly Analyst Ratings
Daiwa Securities Adjusts Price Target on Eli Lilly and Co. to $940 From $800, Maintains Outperform Rating
Citigroup Adjusts Price Target on Pfizer to $30 From $28, Maintains Neutral Rating
Berenberg Bank Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,050